Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Rating Reiterated by HC Wainwright

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $7.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 457.77% from the company’s current price.

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $6.00 price target on shares of Lineage Cell Therapeutics in a report on Monday, February 5th.

Lineage Cell Therapeutics Stock Performance

LCTX stock opened at $1.26 on Monday. Lineage Cell Therapeutics has a twelve month low of $0.84 and a twelve month high of $1.61. The stock has a market cap of $236.94 million, a PE ratio of -9.65 and a beta of 1.39.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Lineage Cell Therapeutics had a negative return on equity of 31.95% and a negative net margin of 240.20%. The company had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $4.74 million. As a group, equities analysts forecast that Lineage Cell Therapeutics will post -0.13 earnings per share for the current fiscal year.

Insider Transactions at Lineage Cell Therapeutics

In other news, Director Don M. Bailey acquired 96,155 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were acquired at an average cost of $1.04 per share, with a total value of $100,001.20. Following the acquisition, the director now directly owns 158,801 shares of the company’s stock, valued at $165,153.04. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 28.10% of the company’s stock.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several large investors have recently modified their holdings of LCTX. Fifth Third Wealth Advisors LLC bought a new position in Lineage Cell Therapeutics in the 1st quarter valued at $30,000. DCF Advisers LLC grew its position in Lineage Cell Therapeutics by 14.5% in the 4th quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after acquiring an additional 12,000 shares during the last quarter. SG Americas Securities LLC grew its position in Lineage Cell Therapeutics by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock valued at $34,000 after acquiring an additional 11,779 shares during the last quarter. Finally, Rathbones Group PLC bought a new position in Lineage Cell Therapeutics in the 3rd quarter valued at $41,000. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.